Introduction {#sec0005}
============

An increasing body of data suggests that outcomes with Coronavirus Disease 2019 (COVID-19) are worse in those suffering from obesity and that a significant proportion of those needing intensive care suffers from overweight or obesity \[[@bib0005]\].

Obesity is affecting most of the physiological processes and modifying the functions of the system including the immune system \[[@bib0010]\]. It is crucial to understand the effect of obesity on the course of infection to prevent or mitigate the morbidities and mortality \[[@bib0015],[@bib0020]\]. In the current COVID-19 era, bariatric teams are aware of the potential risks and thus stressing the extra caution and appropriate management of these patients \[[@bib0025]\]. Knowing the scale of the obesity problem in the world, we anticipate difficult times for this group of patients in Europe, America, Middle East and rest of the world with a high rate of obesity \[[@bib0030]\]. In 2009, a significant percentage of admissions to the hospitals and mortality because of H1N1 Influenza A virus infection was due to obesity, an estimated 151,700--575,400 total deaths was reported \[[@bib0035],[@bib0040]\].

It might not be surprising to see a similar effect with novel COVID-19 infection. Using World Health Organization (WHO) data on the cumulative number of COVID-19 deaths, mortality rates would be 5.6% (95% CI 5.4--5.8) for China and 15.2% (12.5--17.9) outside of China \[[@bib0045]\] which is a gloomy prediction like previous pandemics. Multi strains of the virus are likely identified, but we do not know what impact on the virulence/pathogenesis would be \[[@bib0050],[@bib0055]\]. Although the overall mortality for each country is expected to be different due to other factors such as comparability between healthcare systems, lockdown date, the population size, testing, the timing of the first confirmed case and the criteria of admissions to the hospital \[[@bib0060]\], the implications on the health systems in Europe and America are huge and expected to report the highest mortality in the world.

There are multiple risk factors associated with mortality in COVID-19 patients. Studies had shown diabetes, cardiovascular, cerebrovascular, pulmonary diseases, age and male factors are the predictors of mortality \[[@bib0065], [@bib0070], [@bib0075], [@bib0080], [@bib0085]\].

The vast majority of the COVID-19 studies didn't report obesity as a mortality risk factor due to the lack of the body mass index (BMI)/total body weight (TBW) data or unawareness of obesity risk. The primary endpoint of this research is to investigate obesity as a risk factor for COVID-19 mortality. The secondary endpoints are to assess age, gender, and critical illness, need for advanced respiratory support and associated comorbidities as risk factors for mortality in COVID-19 infection.

We conducted this study to investigate if patients with obesity are more likely to die from COVID-19 compared to non-obese individuals.

We investigated the entire English language scientific literature following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

Methods {#sec0010}
=======

Studies reporting mortality with COVID-19 in patients with and without obesity were independently identified from the published scientific literature by searching PubMed, Embase, Google, Google Scholar, and Springer, Elsevier, the Lancet, AMJ, BMJ, and Oxford journals using keywords like Coronavirus, COVID-19, obesity, obesity mortality during COVID-19, clinical characteristics of COVID-19 patients. Three independent authors \[AH, KM, WY\] screened the titles and abstracts for eligibility. Last of these searches were carried on 1st May. References identified from database searches were exported to EndNote (Clarivate Analytics).

After removal of duplicates, full-text articles were included if their abstracts were considered to be eligible by any author. The full-text of each study was assessed independently, and disagreements were resolved by discussion (we reached 95% overall agreement \[43 out of 45). The studies that reported data on mortality during COVID-19 crisis were included.

We excluded studies that did not separately report on mortality with COVID-19 in patients suffering from overweight or obesity, studies that were small (less than 20 patients) and reports of poor quality data (not including the BMI for mortality, not including the critical illness, the need for invasive respiratory support, the comorbidities). A total of 14 studies were included in our final quantitative analysis. [Fig. 1](#fig0005){ref-type="fig"} gives a PRISMA flow chart \[[@bib0215]\] for article selection.Fig. 1Flow diagram.Fig. 1

Our hypothesis is: Mortality in COVID-19 patients is high among patients with obesity due to large adipose tissue mass with high expression of ACE2 receptors.

The primary objective of this study was to find out the effect of overweight or obesity on patients suffering from COVID-19. Our secondary objectives were to investigate the effect of age, gender, and co-morbidities.

Review Manager (RM) 5.3 software was used for statistical analysis. The P-value of \<0.05 was regarded as significant. For the assessment of the risk of bias in the included studies, the Newcastle--Ottawa system was used ([Table 1](#tbl0005){ref-type="table"} ).Table 1Newcastle--Ottawa quality of study assessment.Table 1Study IDSelectionComparabilityOutcomeTotalRepresentation of the cohortSelection of non exposed cohortAscertainment of the exposureAssessment of the outcomeAdequacy of the outcomeArthur Simonnet 2020 \[[@bib0075]\]⋆--⋆--⋆⋆⋆⋆⋆⋆Bhatraju, 2020 \[[@bib0080]\]⋆--⋆--⋆⋆⋆⋆⋆⋆Caussy C 2020 \[[@bib0085]\]⋆------⋆⋆⋆⋆⋆Fei Zhou 2020 \[[@bib0090]\]⋆⋆⋆⋆⋆⋆⋆⋆⋆⋆⋆ICNARC 2020 \[[@bib0175]\]⋆⋆⋆⋆⋆⋆⋆⋆⋆⋆⋆⋆Jennifer Lighter 2020 \[[@bib0095]\]⋆--⋆--⋆⋆⋆⋆⋆⋆ldh.la.gov 2020 \[[@bib0180]\]⋆--⋆--⋆--⋆⋆⋆Luigi Palmieri, 2020 \[[@bib0185]\]⋆⋆⋆⋆⋆⋆⋆⋆⋆⋆⋆⋆Petrilli 2020 \[[@bib0190]\]⋆⋆⋆--⋆⋆⋆⋆⋆⋆⋆Robert Verity, 2020 \[[@bib0195]\]⋆--⋆--⋆⋆⋆⋆⋆⋆Xiang Bai 2020 \[[@bib0200]\]⋆--⋆--⋆⋆⋆⋆⋆⋆YD Peng 2020 \[[@bib0100]\]⋆--⋆--⋆⋆⋆⋆⋆⋆Xia Unpublished 2020 \[[@bib0205]\]⋆⋆⋆⋆⋆⋆⋆⋆⋆⋆⋆⋆Rong-Hui Du \[[@bib0210]\]⋆⋆⋆⋆⋆⋆⋆⋆⋆⋆⋆⋆

The heterogeneity was reported in this meta-analysis, it ranges from 93 to 98%. Heterogeneity was due to the presence of one or more outlying studies with results that conflict with the rest of the studies. We have addressed this issue by repeating the analysis without outlying studies. Initial statistical analysis showed high heterogeneity among the study, *I* ^2^ was high \>90%. Recalculation and analysis was performed after identifying the study that skewed the results and increased heterogeneity. As a result the *I* ^2^ was 0--61%.

The diagnosis of COVID-19 in the selected studies was made by rRT-PCR (apps.who.it), and also by chest computed tomography CT scan.

Results {#sec0015}
=======

A total of 14 studies\[[@bib0075], [@bib0080], [@bib0085], [@bib0090], [@bib0095], [@bib0100],[@bib0170], [@bib0175], [@bib0180], [@bib0185], [@bib0190], [@bib0195], [@bib0200], [@bib0205], [@bib0210]\] reported on mortality with COVID-19 in patients with and without obesity.

Age: \>70 years old is significant factor for mortality. The included studies of 403,535 patients, 807 patients \<70 year died compared to 881 mortality in 5895 patients \>70 year old. Heterogeneity: Chi² = 90.84, df = 4 (P \< 0.00001); I² = 96%. ([Fig. 2](#fig0010){ref-type="fig"} ). By repeating the analysis after removing outlying studies \[[@bib0195],[@bib0210]\], heterogeneity: Chi² = 2.21, df = 2 (P = 0.33); I² = 9% and the test for overall effect: Z = 8.61 (P \< 0.00001).Fig. 2Mortality among patients age \>70 & \<70 years.Fig. 2

Gender: Male gender is not a significant factor for mortality in COVID-19. There were 4 studies included \[[@bib0090],[@bib0175],[@bib0185],[@bib0210]\].

420 mortality among 1034 men and 182 mortality among 462 women. The odd ratio was 0.89 and the test for overall effect: Z = 1.00 (P = 0.32), Heterogeneity: Chi² = 42.39, df = 3 (P \< 0.00001); I² = 93% ([Fig. 3](#fig0015){ref-type="fig"} ).Fig. 3Mortality according to the gender.Fig. 3

After repeating the test by removing outlying studies \[[@bib0185],[@bib0175]\], the heterogeneity: Chi² = 1.73, df = 1 (P = 0.19); I² = 42% without major change at significant test of overall effect \[test for overall effect: Z = 0.84 (P = 0.40)\].

BMI: there have been 531 deaths among 2451 patients with BMI of \>25 kg/m^2^, while 1701 deaths among 24,056 patients with BMI \< 25 ([Fig. 4](#fig0020){ref-type="fig"} ).Fig. 4Mortality among patients with BMI \> 25 kg/m^2^ and \<25 kg/m^2^.Fig. 4

The data shows Body Mass Index (BMI) to be significantly associated with the mortality (P-value 0.005, OR 3.68, CI 95% ([Fig. 4](#fig0020){ref-type="fig"}). Heterogeneity: Tau² = 0.87; Chi² = 104.32, df = 5 (P \< 0.00001); I² = 95%. Test for overall effect: Z = 2.92 (P = 0.003).

By repeating the analysis after removing studies \[[@bib0080],[@bib0175],[@bib0175]\], heterogeneity is better : Tau² = 0.23; Chi² = 5.16, df = 2 (P = 0.0008); I² = 61%,and the significance test almost the same \[test for overall effect: Z = 1.76 (P = 0.0008)\].

Advanced respiratory support: there have been 648 out of 867 patients with BMI \< 25-needed advanced respiratory support compared to 183 patients with BMI \> 25 of total 630 patients ([Fig. 5](#fig0025){ref-type="fig"} ). Patients with BMI \> 25 kg/m^2^ are significantly more likely to need advanced respiratory support (P-value 0.00001, OR 6.98, CI 95%) ([Fig. 5](#fig0025){ref-type="fig"}). Heterogeneity: Chi² = 16.72, df = 3 (P = 0.0008); I² = 82% test for overall effect: Z = 14.54 (P \< 0.00001).Fig. 5Needs for advanced and basic respiratory support among patients with BMI \> 25 kg/m^2^ and \<25 kg/m^2^.Fig. 5

By repeating the analysis without outlying one study data \[[@bib0205]\], heterogeneity: Chi² = 1.35, df = 2 (P = 0.51); I² = 0%. Test for overall effect: Z = 12.89 (P \< 0.00001).

Severe comorbidities: mortality among patients with severe comorbidities is significantly higher than no severe comorbidities, P-value \<0.00001, OR 1.84, CI 955. ([Fig. 6](#fig0030){ref-type="fig"} ). Heterogeneity: Chi² = 121.03, df = 4 (P \< 0.00001); I² = 97%. Repeating analysis after removing the outlying studies \[[@bib0100],[@bib0185],[@bib0200]\], heterogeneity: Chi² = 0.96, df = 1 (P = 0.33); I² = 0%. Test for overall effect: Z = 2.33 (P = 0.02).Fig. 6Mortality among patients with and without severe comorbidities.Fig. 6

Critical illness: 463 deaths among 1186 patients with BMI \> 30 compared to 619 deaths among 3425 patients with BMI \< 30. Obesity is a significant factor for critical illness during COVID-19, P-value \<0.00001, OR 2.03, CI 95% (see [Fig. 7](#fig0035){ref-type="fig"} ).Fig. 7Critical illness among patients with BMI \> 25 kg/m^2^ and \<25 kg/m^2^.Fig. 7

By removing outlying one study \[[@bib0190]\], the heterogeneity: Chi² = 0.14, df = 1 (P = 0.71); I² = 0%. Test for overall effect: Z = 15.39 (P \< 0.00001).

Discussion {#sec0020}
==========

The most important findings of this paper are obesity was an important associated factor for mortality in patients with COVID-19. This most likely because the patients in obesity were known to have a defective immune system that makes them vulnerable to a type of infection that specifically require a prompt cellular immunity response \[[@bib0090]\].

Obesity impairs immunity by altering the response of cytokines, resulting in a decrease in the cytotoxic cell response of immunocompetent cells which have a key anti-viral role in addition to disturb the balance of endocrine hormones, such as leptin, that affect the interplay between metabolic and immune systems \[[@bib0095]\]. Obesity also leads to the involvement of adipose tissue-specific molecules (adipokines) in the generation of an environment that is favorable for diseases with an immune cause \[[@bib0100]\]. The dendritic cells (DCs) with crucial linking role between innate and adaptive immunity, produced twofold more of the immunosuppressive cytokine interleukin (Bello-Chavolla, \#2)-10 than lean controls, and in turn stimulated fourfold more IL-4-production from allogeneic T cells. There are also negative impacts of the ability of DCs to mature and elicit appropriate T-cell responses to a general stimulus like viral infection \[[@bib0105]\].

Human angiotensin-converting enzyme 2 (ACE2) is the putative receptor for the entry of SARS-CoV2 into target cells with remarkably high affinity \[[@bib0110]\]. It is noteworthy that the level of expression of ACE2 in adipose tissue is reported to be higher than in lung tissue. The expression of ACE2 receptors is the same for adipose tissue in obese and non-obese patients but the difference is in the mass of the adipose tissues that made patients with obesity expressing high number of ACE2 receptors. This increment could explain why patients with obesity are showing severe form of the Covid-19 \[[@bib0115]\].

Chronic adipose tissue inflammation in obesity is influencing the activity of cells of innate and adaptive immunity \[[@bib0120]\]. Not only natural killer, macrophages, and neutrophils, but also underlying immune impairment in the responsiveness of lymphocytes is reported \[[@bib0125]\]. These changes are associated with an overall negative impact on chronic disease progression, immunity from infection, and vaccine efficacy in patients in obesity \[[@bib0130]\]. Statistical analysis of the patients who developed the severe disease and died in ITU suggested a significant association with obesity, and no surprise of the outcome if we understand the defective immune response highlighted above. The fact that obesity is usually a clustered of diseases leading to metabolic syndrome, making the previously confirmed mortality-predicting factors of diabetes, hypertension, cardiovascular diseases and other obesity-associated comorbidities as indirect evidence pointing to the obesity in well-conducted studies that did not include obesity data \[[@bib0070],[@bib0085]\].

This study has confirmed patients above the age of 70 are likely to die from COVID-19, the same finding was confirmed in many other studies \[[@bib0080],[@bib0135],[@bib0140]\], which is expected outcome anyway. The other important results were mortality was not significantly different between men and women in general analysis, although it inclined towards men but does not reach statistical significance. This was also shown in the previous studies \[[@bib0070],[@bib0135],[@bib0145]\].

Patients in obesity are more likely to develop a critical illness than that of non-obesity \[[@bib0150], [@bib0155], [@bib0160]\]. It is crucial to note that patients with obesity not only suffer from their obesity but also from other metabolic disorders such as diabetes. This point should not be ignored because the cumulative risk of mortality increases with obesity-associated comorbidities. This indirectly refers to the metabolic syndrome and obesity-related comorbidities such as diabetes, hypertension, cardiac and cerebrovascular diseases. Several other studies had shown the same findings \[[@bib0145],[@bib0165]\].

The other important outcome was the need for advanced respiratory support was significantly higher in patients in obesity. This is because of the detrimental effect of obesity on the lung volumes, functions and expansions in addition to the severity of the illness and magnitude of lung inflammation and damage in patients in obesity \[[@bib0145]\]. It goes without doubt that severe comorbidities are a risk factor for mortality in patients in obesity due to a defective immune system, under-functioning respiratory and cardiovascular systems, renal disease, diabetes, etc. This study has confirmed a significant association between comorbidities and mortality in patients in obesity.

Using the OR of the available data we were able to produce a scoring mortality model for patients in obesity with COVID-19 infection (see [Table 2](#tbl0010){ref-type="table"} ). This scoring system can be used to improve the care by identifying the high-risk patients.Table 2Using the odd ratio (OR) of the available data to produce a scoring mortality model for COVID-19 infection.Table 2ParametersOR valueAge \< 70FemaleBMI \< 25No severe comorbiditiesNo critical illnessNo advanced respiratory supportAge \> 700.170Age \< 70Age \< 70Age \< 70Age \< 70Age \< 70Male0.890.890FemaleFemaleFemaleFemaleBMI \> 253.683.683.680MBI \< 25BMI \< 25BMI \< 25Severe comorbidities1.841.841.841.840No severe comorbiditiesNo severe comorbiditiesCritical illness2.032.032.032.032.030No critical illnessAdvanced respiratory support6.986.986.986.986.986.980Total15.5915.4214.5310.859.016.980

Limitations of the study {#sec0025}
========================

This study included retrospective clinical reports suffer from some biases, the risk of biases was reported in methodology. There was a high grade of heterogeneity of the data. This was addressed by repeating the analysis after removing the outlying study data. There was no change in the overall test of significance, P-value remains \<0.05. The heterogeneity reduced significantly and ranged from 0 to 61%. There was a lack of some data and were calculated indirectly from percentage and other provided parameters. There was one unpublished study data from China and the other 12 studies. Over two months period of search, we were aiming to include all available reports on mortality of obesity in COVID-19 infection, however, we may have missed some important studies that potentially affect the overall effects and conclusion from this meta-analysis. The populations studied differ in their comorbidities and severity. The definition of severe form is not consensual. The WHO defines overweight as BMI ≥ 25 kg/m^2^ and obesity as BMI ≥ 30 kg/m^2^. However, the Chinese-specific cut-off values for general adiposity define normal weight as BMI 18.5--23.9 kg/m^2^, overweight as BMI 24.0--27.9 kg/m² and obesity as BMI ≥ 28 kg/m². COVID-19 mortality in children with obesity was not included and therefore not discussed.

Conclusions {#sec0030}
===========

Obesity is a risk factor for mortality in COVID-19. Age, critical illness, need for advanced respiratory support and severe comorbidities are also risk factors for mortality.
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